As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...

Alcon is building out its portfolio of lens implants, with a $1.5 billion deal to acquire the flagging Staar Surgical and its ...

A phase 2b trial of HMNC Brain Health’s depression drug candidate has missed its primary endpoint. But while the ex-Sanofi molecule failed to move the needle in the overrall population, results in ...

Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 ...

Pfizer has abanonded yet another GLP-1 drug from its shrinking obesity pipeline, as well as dumping a Clostridium difficile ...

BioMarin is continuing to slim down its pipeline, this time ending work on a preclinical phenylketonuria (PKU) drug once ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

The FDA formally kicked off its quinquennial process to reauthorize the federal user fee legislation that helps fund its ...

A Senate committee has rejected President Donald Trump’s efforts to gouge funding for the National Institutes of Health (NIH) ...

The brain-computer interface developer Synchron has shown that its minimally invasive device can help connect a patient with ...

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

OrbiMed’s website lists 134 biopharma companies across the firm’s portfolio. Recent investments the firm has participated in ...